NOV

Novo Nordisk A/S Class B · TRADEGATE:NOV

35.41 EUR−0.3500 −0.98%

Novo Nordisk A/S Class B (TRADEGATE:NOV) last traded at 35.41 EUR, down 0.98% on the day. Over the past year the stock is down 18.53%. Its 52-week range is 30.25 to 54.86. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open35.83

Day range35.35 – 35.88

52-week range30.25 – 54.86

Volume70.22 K

Average volume (10 days)137.43 K

Market cap (USD)175.64 B

P/E10.13

EPS (TTM) (USD)3.99

Dividend yield4.40%

Beta (1 year)0.5779

Revenue (TTM) (USD)50.21 B

Employees68.79 K

Performance

+1.77%1 week

+6.59%1 month

−13.58%3 months

−8.10%6 months

−19.20%Year to date

−18.53%1 year

Technical reading

Neutral

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. SuperCharting is charting software and gives no investment advice.